Ad5
Showing 1 - 25 of 9,742
COVID-19 Trial in Nanjing (Ad5-nCoV-IH, Ad5-nCoV-IM, CoronaVac)
Active, not recruiting
- COVID-19
- Ad5-nCoV-IH
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Diseases Control and Prevention
Aug 12, 2022
COVID-19 Trial in Yancheng (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel
Active, not recruiting
- COVID-19
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
-
Yancheng, Jiangsu, ChinaFuning Center for Disease Control and Prevention
Oct 28, 2022
COVID-19 Trial in Lianyungang (batch 1 of Ad5-nCoV, batch 2 of Ad5-nCoV, batch 3 of Ad5-nCoV)
Completed
- COVID-19
- batch 1 of Ad5-nCoV
- +2 more
-
Lianyungang, Jiangsu, ChinaGuanyun Center for Disease Control and Prevention
Apr 5, 2022
COVID-19 Trial in Nanjing (Recombinant SARS-CoV-2 Ad5 vectored vaccine, Inactive SARS-CoV-2 vaccine (Vero cell))
Completed
- COVID-19
- Recombinant SARS-CoV-2 Ad5 vectored vaccine
- Inactive SARS-CoV-2 vaccine (Vero cell)
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Disease Control and Prevention
Mar 28, 2022
COVID-19 Trial in Nanjing (recombinant Ad5 vectored COVID-19 vaccine, RBD-based protein subunit vaccine (ZF2001) against
Completed
- COVID-19
- recombinant Ad5 vectored COVID-19 vaccine
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Diseases Control and Prevention
Mar 28, 2022
COVID-19 Trial in Nanjing (Intramuscularly administered Ad5-nCoV vaccine, Aerosolized Ad5-nCoV, DelNS1-2019-nCoV-RBD-OPT1)
Not yet recruiting
- COVID-19
- Intramuscularly administered Ad5-nCoV vaccine
- +3 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Disease Control and Prevention
May 10, 2023
COVID-19, SARS-CoV2 Infection Trial in Hamilton (Ad5-triCoV/Mac, ChAd-triCoV/Mac)
Recruiting
- COVID-19
- SARS-CoV2 Infection
- Ad5-triCoV/Mac
- ChAd-triCoV/Mac
-
Hamilton, Ontario, CanadaMcMaster University Medical Centre
Jun 15, 2022
Angina, Stable Trial (Ad5FGF-4, Placebo)
Not yet recruiting
- Angina, Stable
- Ad5FGF-4
- Placebo
- (no location specified)
Jul 18, 2022
COVID-19 Trial in Wuhan (Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For
Recruiting
- COVID-19
- Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation
- +2 more
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Jun 1, 2023
COVID-19 Trial (Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), Bivalent Recombinant COVID-19 Vaccine
Not yet recruiting
- COVID-19
- Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
- +2 more
- (no location specified)
Jul 5, 2022
COVID-19 Trial in Taizhou (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant Novel Coronavirus
Completed
- COVID-19
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
-
Taizhou, Jiangsu, ChinaTaixing City center for Disease Control and Prevention
Oct 28, 2022
COVID-19 Trial (Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), Placebo)
Not yet recruiting
- COVID-19
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
- Placebo
- (no location specified)
Nov 19, 2021
Norovirus Infections Trial in Cypress (VXA-G1.1-NN)
Completed
- Norovirus Infections
- VXA-G1.1-NN
-
Cypress, CaliforniaWCCT Global, Inc.
Sep 19, 2022
COVID-19 Trial (1 Nebulized inhalation for booster groups, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for
Recruiting
- COVID-19
- 1 Nebulized inhalation for booster groups
- +23 more
-
Xiangxi, Hunan, ChinaCDC of of Luxi County, Xiangxi Tujia and Miao Autonomous Prefect
Oct 24, 2022
SARS-CoV-2 Infection Among Healthcare Workers
Recruiting
- COVID-19
- inactivated COVID-19 vaccines; orally aerosolized Ad5-nCoV
-
Nanjing, Jiangsu, ChinaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University
Jan 10, 2023
Lung Cancer Trial (TILT-123, Pembrolizumab)
Not yet recruiting
- Lung Cancer
- TILT-123
- Pembrolizumab
- (no location specified)
Nov 5, 2023
COVID-19 Vaccine Trial in Ciudad autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aire, Ciudad Autónoma de Buenos Aires
Active, not recruiting
- COVID-19 Vaccine
- Ad5-nCov
-
Ciudad autónoma de Buenos Aires, Buenos Aires, Argentina
- +2 more
Sep 28, 2022
Norovirus Infections Trial in Cypress, New Orleans, Austin (VXA-GI.1.NN, Placebo Tablet)
Completed
- Norovirus Infections
- VXA-GI.1.NN
- Placebo Tablet
-
Cypress, California
- +2 more
Sep 19, 2022
Alzheimer's Disease Trial in Changsha (AD16 5mg?10mg?20mg?30mg?40mg?60mg?80mg, AD16 5mg?10mg?20mg?30mg?40mg?60mg?80mg)
Completed
- Alzheimer's Disease
- AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg
- AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg
-
Changsha, ChinaThe Central South University Xiang Ya Hospital
Mar 14, 2023
COVID-19 Trial (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant COVID-19 vaccine (adenovirus type
Not yet recruiting
- COVID-19
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
- (no location specified)
Jan 11, 2022
Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma Trial in Philadelphia (Adenovirus
Recruiting
- Pancreatic Ductal Adenocarcinoma
- +37 more
- Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Nov 2, 2021
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma Trial in Detroit (Ad5-yCD/mutTKSR39rep-ADP adenovirus and
Recruiting
- Malignant Glioma of Brain
- +8 more
- Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
-
Detroit, MichiganHenry Ford Health System
Jan 9, 2023
Covid19 Trial in Caba, Capital Federal (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV))
Recruiting
- Covid19
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
-
Caba, Buenos Aires, Argentina
- +3 more
Sep 14, 2021
SARS-CoV-2 Infection Trial in Bangkok (Full dose of Ad26.COV2. 5x10^10vp, Half dose of Ad26.COV2. 2.5x10^10vp)
Recruiting
- SARS-CoV-2 Infection
- Full dose of Ad26.COV2. 5x10^10vp
- Half dose of Ad26.COV2. 2.5x10^10vp
-
Bangkok, ThailandVaccine Trial Centre, Faculty of Tropical Medicine, Mahidol Univ
Sep 11, 2022
Glycemic Control, Satiety Response, Appetite Regulation Trial in Toronto (Ad libitum full-fat French fries with beef meatballs,
Not yet recruiting
- Glycemic Control
- +4 more
- Ad libitum full-fat French fries with beef meatballs
- +5 more
-
Toronto, Ontario, CanadaUniversity of Toronto - Department of Nutritional Sciences
Nov 1, 2022